<DOC>
	<DOCNO>NCT01332968</DOCNO>
	<brief_summary>This open-label , randomize study ass efficacy safety obinutuzumab ( RO5072759 ) combination chemotherapy compare MabThera/Rituxan ( rituximab ) chemotherapy follow obinutuzumab MabThera/Rituxan maintenance patient untreated advanced indolent non-Hodgkin 's lymphoma . After end induction period , patient achieve response ( CR PR ) go maintenance period thereby continue randomize antibody treatment alone every 2 month disease progression total 2 year . Anticipated time study treatment approximately 2.5 year . After maintenance observation patient follow 5 year progression . After progression , patient follow new anti-lymphoma therapy overall survival end study .</brief_summary>
	<brief_title>A Study Obinutuzumab ( RO5072759 ) Plus Chemotherapy Comparison With MabThera/Rituxan ( Rituximab ) Plus Chemotherapy Followed GA101 MabThera/Rituxan Maintenance Patients With Untreated Advanced Indolent Non-Hodgkin 's Lymphoma ( GALLIUM )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age CD20positive indolent Bcell nonHodgkin 's lymphoma ( follicular lymphoma splenic , nodal extranodal marginal zone lymphoma ) Stage III IV disease , Stage II bulky disease ( define tumour diameter &gt; /= 7 cm ) , require treatment For patient follicular lymphoma : requirement treatment accord GELF criterion For patient symptomatic marginal zone lymphoma : disease de novo relapse follow local therapy ( i.e . surgery radiotherapy ) require therapy assess investigator At least one bidimensionally measurable lesion ( &gt; 2 cm large dimension CT scan MRI ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate hematologic function Central nervous system lymphoma , leptomeningeal lymphoma , histological evidence transformation highgrade diffuse large Bcell lymphoma Grade 3b follicular lymphoma , small lymphocytic lymphoma Waldenstr√∂m 's macroglobulinaemia Ann Arbor Stage I disease History severe allergic anaphylactic reaction monoclonal antibody therapy , know hypersensitivity study drug sensitivity murine product , history sensitivity mannitol For patient follicular lymphoma : prior treatment nonHodgkin 's lymphoma chemotherapy , immunotherapy , radiotherapy For patient nonfollicular lymphoma : prior treatment chemotherapy immunotherapy Regular treatment corticosteroid 4 week prior start Cycle 1 Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result For patient receive CHOP : LVEF &lt; 50 % MUGA scan echocardiogram History prior malignancy exception curatively treat basal squamous cell carcinoma skin lowgrade situ carcinoma cervix Known active infection , major episode infection within 4 week prior start Cycle 1 Vaccination live vaccine within 28 day prior randomization Recent major surgery ( within 4 week prior start Cycle 1 ) , diagnosis Abnormal laboratory value define protocol creatinine , creatinine clearance , AST ALT , total bilirubin , INR , PTT aPPT , unless abnormality due underlie lymphoma Positive per protocol definition HIV , HTLV1 , hepatitis C chronic hepatitis B Pregnant lactate woman Life expectancy &lt; 12 month Participation another clinical trial drug intervention within 28 day prior start Cycle 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>